Spero Therapeutics, Inc. (NASDAQ:SPRO) Receives $5.00 Consensus PT from Analysts

Spero Therapeutics, Inc. (NASDAQ:SPRO) has been given an average rating of “Hold” by the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $5.00.

A number of research firms have issued reports on SPRO. Zacks Research downgraded shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Wednesday, October 8th.

Spero Therapeutics Stock Performance

NASDAQ:SPRO opened at $2.36 on Tuesday. The company has a market cap of $132.82 million, a price-to-earnings ratio of -2.41 and a beta of 1.47. The stock’s fifty day moving average price is $2.09 and its two-hundred day moving average price is $1.97. Spero Therapeutics has a 52-week low of $0.51 and a 52-week high of $3.22.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Tuesday, August 12th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.35. The company had revenue of $14.19 million during the quarter, compared to the consensus estimate of $11.00 million. Spero Therapeutics had a negative return on equity of 120.27% and a negative net margin of 110.35%. On average, equities analysts predict that Spero Therapeutics will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Spero Therapeutics

Institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. acquired a new position in Spero Therapeutics in the third quarter valued at about $70,000. Stonepine Capital Management LLC acquired a new stake in shares of Spero Therapeutics in the 2nd quarter valued at approximately $455,000. Invesco Ltd. bought a new position in Spero Therapeutics during the 2nd quarter worth approximately $43,000. Quadrature Capital Ltd acquired a new position in Spero Therapeutics during the second quarter valued at approximately $90,000. Finally, XTX Topco Ltd bought a new stake in Spero Therapeutics in the second quarter valued at approximately $100,000. 25.60% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.